Immuno-Oncology (I-O) pathway configuration project (IPC project): A joint working project between Velindre NHS Trust (VCC) & Bristol-Myers Squibb (BMS)

Executive Summary

Introduction

Velindre Cancer Centre, Velindre NHS Trust and Bristol-Myers Squibb Pharmaceuticals Ltd entered into a joint working agreement to design and plan a high-quality and patient focused service configuration that can accommodate the expected increase in oncology patient numbers and demand on services.

The benefits to patients included an improved patient experience through provision of a streamlined, efficient and patient-focused service. The benefits to the NHS included planning for prudent use of health care resources and resilience of services. Bristol-Myers Squibb were committed to demonstrating leadership in Immuno-oncology therapies in Wales through their participation in this project.

The outputs of the project were

- A piloted service model aimed at reducing the burden on oversubscribed treatment assessment clinics and benefitting patients by reducing the time spent in outpatient clinics in addition to reducing the frequency of hospital visits.
- An assessment of potential future patient demand at Velindre, provided as an output from BMS’s Demand Assessment Model, in order to inform modelling of revised pathways and resources based on potential increased patient demand.

Conclusion

The project closed in February 2018, in line with the agreement. Velindre Cancer Centre and Bristol-Myers Squibb have reflected that working together and delivering the project yielded great experience for both parties. Structured plans were developed for delivery of the project, and throughout the course of the work, both parties engaged in tackling the challenges. The joint working project has yielded some positive outputs that are reflected in this summary.